Ebru Temiz1, Kadir Eği2, Ismail Koyuncu3, Ozgür Yüksekdag2, Yusuf Kurt4, Murat Tiken2, Sükrü Akmese2. 1. Medical Promotion and Marketing Program, Health Services Vocational School, Harran University, Şanlıurfa, Turkey. 2. Department of Medicinal Biochemistry, Medical Faculty, Harran University, Şanlıurfa, Turkey. 3. Department of Medicinal Biochemistry, Medical Faculty, Harran University, Şanlıurfa, Turkey. ikoyuncu@harran.edu.tr. 4. Department of Molecular Biology and Genetic, Science Faculty, Harran University, Şanlıurfa, Turkey.
Abstract
BACKGROUND: Many chemotherapeutic drugs used in cancer treatment have anticancer properties by inducing reactive oxygen species (ROS). However, the same effect occurs in normal cells, limiting the availability of these drugs. Therefore, studies on the detection of new herbal anticancer agents that have selective effects on cancer cells are of great importance. The aim of this study is to investigate the metabolite profile of Cedrus libani tar and its mechanism of anticancer effect on colon cancer cells. METHODS AND RESULTS: Effect of cedar tar on cells (12 cancers and 5 normal cell lines) viability was determined by MTT, apoptosis induction was determined by Annexin-V, ROS and MMP determined by flow cytometry assay. Cleaved caspase-8, 9 and Ɣ-H2AX expression determined by western blot. Apoptotic and antioxidant genes expression level determined by qPCR. Metabolite profiling was performed with LC-MS/MS and GC-MS. Cedar tar showed the highest cytotoxic effect among cancer cells in colon cancer (HCT-116, IC50: 30.4 μg/mL) and its toxic effect on normal cells (HUVEC, IC50: 74.07 μg/mL) was less than cancer cell. Cedar tar increases ROS production in colon cancer cells. The metabolite profile of the cedar tar contains high amounts of metabolites such as fatty acids mainly (Duprezianene, Himachalene and Chamigrene), phenolic compounds (mostly Coumarin, p-coumaric acid, Vanillic acid and tr-Ferulic acid etc.) and organic acids (mainly 3-oh propanoic acid, 2-oh butyric acid and 3-oh isovaleric acid etc.). CONCLUSION: As a result, it has been found that cedar tar has the potential to be used in the treatment of colon cancer.
BACKGROUND: Many chemotherapeutic drugs used in cancer treatment have anticancer properties by inducing reactive oxygen species (ROS). However, the same effect occurs in normal cells, limiting the availability of these drugs. Therefore, studies on the detection of new herbal anticancer agents that have selective effects on cancer cells are of great importance. The aim of this study is to investigate the metabolite profile of Cedrus libani tar and its mechanism of anticancer effect on colon cancer cells. METHODS AND RESULTS: Effect of cedar tar on cells (12 cancers and 5 normal cell lines) viability was determined by MTT, apoptosis induction was determined by Annexin-V, ROS and MMP determined by flow cytometry assay. Cleaved caspase-8, 9 and Ɣ-H2AX expression determined by western blot. Apoptotic and antioxidant genes expression level determined by qPCR. Metabolite profiling was performed with LC-MS/MS and GC-MS. Cedar tar showed the highest cytotoxic effect among cancer cells in colon cancer (HCT-116, IC50: 30.4 μg/mL) and its toxic effect on normal cells (HUVEC, IC50: 74.07 μg/mL) was less than cancer cell. Cedar tar increases ROS production in colon cancer cells. The metabolite profile of the cedar tar contains high amounts of metabolites such as fatty acids mainly (Duprezianene, Himachalene and Chamigrene), phenolic compounds (mostly Coumarin, p-coumaric acid, Vanillic acid and tr-Ferulic acid etc.) and organic acids (mainly 3-oh propanoic acid, 2-oh butyric acid and 3-oh isovaleric acid etc.). CONCLUSION: As a result, it has been found that cedar tar has the potential to be used in the treatment of colon cancer.
Authors: Avni G Desai; Ghulam N Qazi; Ramesh K Ganju; Mahmoud El-Tamer; Jaswant Singh; Ajit K Saxena; Yashbir S Bedi; Subhash C Taneja; Hari K Bhat Journal: Curr Drug Metab Date: 2008-09 Impact factor: 3.731
Authors: N J Kassebaum; A G C Smith; E Bernabé; T D Fleming; A E Reynolds; T Vos; C J L Murray; W Marcenes Journal: J Dent Res Date: 2017-04 Impact factor: 6.116